Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 452 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Providence Alaska Medical Center — Anchorage, Alaska
+ 390 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 155 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Locations: - University of Alabama At Birmingham Hospital — Birmingham, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- Ucsf Fresno — Fresno, California
+ 38 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Locations: - Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Locations: - Local Institution - 0225 — Birmingham, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- Alaska Oncology and Hematology — Anchorage, Alaska
+ 28 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Locations: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope Cancer Center — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Locations: - Mayo Clinic Cancer Center — Phoenix, Arizona
- HonorHealth Cancer Center — Scottsdale, Arizona
- Providence Medical Foundation — Fullerton, California
+ 20 more sites in the U.S.
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Locations: - Palo Verde Hematology Oncology — Glendale, Arizona
- Hoag Hospital Newport Beach — Newport Beach, California
- University of California, Irvine Health — Orange, California
+ 20 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Locations: - Mayo Clinic Arizona — Scottsdale, Arizona
- Highlands Oncology Group — Fayetteville, Arkansas
- Rocky Mountain Cancer Centers — Denver, Colorado
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Locations: - Ascentage Investigative Site — Tuscon, Arizona
- Ascentage Investigative Site — Anaheim, California
- Ascentage Investigative Site — Jacksonville, Florida
+ 8 more sites in the U.S.